

8th

Lung Cancer Seminar

23-25 September 2022 Cultural Foundation of Tinos

Tinos Island
GREECE

www.8thlungcancerseminar.gr



ακτινοθεραπεία


μεσοθωρακίου μετά από
χειρουργείο

Ιωάννης Γεωργακόπουλος
Ακτινοθεραπευτής Ογκολόγος

epidemiology


Estimated New Cases

		Males	Females		
Prostate	268,490	27%	Breast	287,850	31%
Lung & bronchus	117,910	12%	Lung & bronchus	118,830	13%
Colon & rectum	80,690	8%	Colon & rectum	70,340	8%
Urinary bladder	61,700	6%	Uterine corpus	65,950	7%
Melanoma of the skin	57,180	6%	Melanoma of the skin	42,600	5%
Kidney & renal pelvis	50,290	5%	Non-Hodgkin lymphoma	36,350	4%
Non-Hodgkin lymphoma	44,120	4%	Thyroid	31,940	3%
Oral cavity & pharynx	38,700	4%	Pancreas	29,240	3%
Leukemia	35,810	4%	Kidney & renal pelvis	28,710	3%
Pancreas	32,970	3%	Leukemia	24,840	3%
All Sites	983,160	100%	All Sites	934,870	100%



Estimated Deaths

		Males	Females		
Lung & bronchus	68,820	21%	Lung & bronchus	61,360	21%
Prostate	34,500	11%	Breast	43,250	15%
Colon & rectum	28,400	9%	Colon & rectum	24,180	8%
Pancreas	25,970	8%	Pancreas	23,860	8%
Liver & intrahepatic bile duct	20,420	6%	Ovary	12,810	4%
Leukemia	14,020	4%	Uterine corpus	12,550	4%
Esophagus	13,250	4%	Liver & intrahepatic bile duct	10,100	4%
Urinary bladder	12,120	4%	Leukemia	9,980	3%
Non-Hodgkin lymphoma	11,700	4%	Non-Hodgkin lymphoma	8,550	3%
Brain & other nervous system	10,710	3%	Brain & other nervous system	7,570	3%
All Sites	322,090	100%	All Sites	287,270	100%




role of adjuvant RT

adjuvant RT in completely resected NSCLC



PORT Metaanalysis of RCTs

Trial	Number of events/ number entered				Hazard ratio
	PORT	No PORT	O-E	Variance	
Belgium (10)	88/98	80/104	16.04	40.67	
LCSG 773 (11)	84/110	81/120	4.77	41.02	
CAMS (12)	83/153	100/164	1.07	44.88	
Lille (13)	59/81	45/82	10.87	25.66	
EORTC 08861	26/52	20/54	5.53	11.20	
MRC LU11 (14)	116/154	123/154	-2.48	59.39	
GETCB 04CB86	69/99	59/90	4.95	31.59	
Slovenia (15)	30/35	33/39	-2.56	15.63	
GETCB 05CB88	152/274	120/265	25.13	67.08	
Total	707/1056	661/1072	63.32	337.12	




adjuvant RT in NSCLC

PORT Metaanalysis of RCTs



adjuvant RT in NSCLC


PORT Metaanalysis of RCTs



adjuvant RT in NSCLC


updated PORT Metaanalysis of RCTs

	(no. events/no. entered)	
	S + RT	S
Belgium	88/98	80/104
LCSG 773	84/110	81/120
CAMS	83/153	100/164
Lille	59/81	45/82
EORTC 08861	26/52	20/54
MRC LU11	116/154	123/154
GETCB 04CB86	69/99	59/90
Slovenia	30/35	33/39
GETCB 05CB88	152/274	120/265
Italy (3)	23/51	30/53
Total	730/1107	691/1125



adjuvant RT in NSCLC

PORT Metaanalysis of RCTs



PORT Metaanalysis Trialists Group, *Lancet* 1998

PORT Metaanalysis Trialists Group, *Lung Cancer* 2005

adjuvant RT in NSCLC guidelines

- early stage
- locally advanced

R1 – R2 resection

upstaged surgically to pN2

stage IIIA pN2



National
Comprehensive
Cancer
Network®



R1 – R2 resection in early stage NSCLC